Report-Breaking Income of HK$586.2M and EPS Surged to HK$1.56 Cents
Dividends Distributed for Two Consecutive Years
Embarks on Innovation-Pushed Transformation to Develop into a International Pioneer in Regenerative Drugs
HONG KONG SAR – EQS Newswire – 27 March 2026 – A totally built-in biopharmaceutical firm – Uni-Bio Science Group Restricted (“Uni-Bio Science”, along with its subsidiaries known as the “Group”, inventory code: 0690.HK), is happy to announce its annual outcomes for the yr ended 31 December 2025 (the “Yr”).
Key Accomplishments in 2025
In the course of the Yr, the Group achieved a spectrum of accomplishments, for each of its marketed merchandise and revolutionary biologics. The important thing highlights embody:
- In the course of the Yr, the Group delivered record-breaking monetary outcomes, with income recorded a 6.0% year-on-year (“YoY”) enhance, reaching roughly HK$586.2 million. Revenue for the yr soared by 12.7% YoY to roughly HK$93.3 million, and web revenue margin elevated by 1.0 share factors YoY to fifteen.9%, marking a historic excessive. The earnings per share reached roughly HK$1.56 cents, reflecting a development of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025.
- The Group generated stable money from operations within the Yr, working money circulation and free money circulation elevated by 32.7% and 27.3% YoY, respectively. Money ratio elevated from 0.53 occasions on the finish of 2024 to 1.63 occasions on the finish of 2025. The money conversion cycle improved from 124 days to 107 days, highlighting better working effectivity. Backed by sustainable earnings and a wholesome money circulation, the board of administrators (“Board”) has declared a dividend fee for 2025 of HK$0.313 cents per share.
- Since its official launch in March 2024, Bogutai® has sustained sturdy development momentum, pushed by a stable commercialization technique and profitable educational engagement. In 2025, Bogutai® demonstrated speedy market adoption in China, reaching a outstanding year-on-year income development of 111.0%.
- In Might 2025, the Group’s second ophthalmology product, 金因康® (Diquafosol Sodium Eye Drops), obtained advertising and marketing approval from the China Nationwide Medical Merchandise Administration (“NMPA”), marking a major milestone in increasing the Group’s ophthalmic portfolio following GeneSoft®. The Group is actively getting ready its launch and advertising and marketing technique. Along with leveraging synergy with GeneSoft® and its established on-line and offline distribution community for speedy market penetration, 金因康® will particularly goal the mid-to-high-end section of dry eye sufferers outdoors the hospital setting, those that prioritize long-term efficacy and premium product high quality.
- In June 2025, the Group formally launched the high-end collection GeneQueens® of 肌顏態® and the medical machine model 金因敷®, marking two key milestones in its strategic growth into the built-in”Drug, Medical System, and Aesthetics”discipline. These product launches mirror the Group’s dedication to enhancing its pores and skin well being product matrix and addressing evolving client wants for efficacy-driven, medical-grade skincare in each practical skincare and post-aesthetic restoration.
- In July 2025, the advertising and marketing software of Isavuconazonium sulfate capsules have been formally accepted by the NMPA. Isavuconazonium sulfate capsules are anticipated to be accredited for launch as early because the fourth quarter of 2026, providing a safer, more practical, and high-quality remedy possibility for sufferers affected by invasive fungal infections.
- In 2025, the Group established a strategic partnership with Wenzhou Medical College to discover a thermosensitive gel formulation combining EGF and bFGF, leveraging the college’s confirmed experience in bFGF manufacturing. As a key development think about regenerative medication, bFGF is very efficient in selling granulation and angiogenesis.
- In the direction of the top of 2025, the Group repositioned its long-term technique from “Steady Development” to “Innovation-Pushed,” signifying a daring transformation from an built-in pharmaceutical firm into a world pioneer in regenerative medication. The Group is advancing a transformative R&D technique spanning 4 key areas: muscular-skeletal regeneration, pores and skin regeneration, ocular regeneration, and ENT regeneration.
Annual Outcomes
For 2025, the Group recorded a income of roughly HK$586.2 million, representing a rise of 6.0% YoY. Income from Bogutai® elevated from roughly HK$ $63.5 million to roughly HK$ 134.0 million, representing a major enhance of 111.0%. Income generated from GeneTime® was roughly HK$220.4 million, representing a rise of 10.9% YoY. GeneSoft® recorded a 7.9% YoY lower in income from roughly HK$41.9 million to roughly HK$38.6 million because of intense market competitors. Pinup® recorded a lower of 29.4% in income from roughly HK$244.2 million to roughly HK$172.5 million for the Yr. In 2025, the Group adopted a extra disciplined and selective hospital-supply technique beneath volume-based procurement (VBP) to safeguard margins, notably in areas the place coverage changes intensified worth competitors. On the identical time, the Group accelerated diversification into pharmacy networks past conventional hospital channels and optimized its provide chain to enhance value and profitability. In 2024, Boshutai® was efficiently included within the VBP by the Henan Seventeen Provinces Alliance and the procurement validity interval is about for 2 years. Hospitals in lots of provinces started procuring Boshutai® in 2025. Following the destocking and a low base in 2024, income from Boshutai® elevated from roughly HK$10.2 million to roughly HK$15.5 million, representing a major enhance of 51.9%. 肌顏態® generated roughly HK$2.8 million in income in its early stage. The restricted income scale mirrored a number of components, together with a comparatively small variety of merchandise accredited and launched in the course of the Yr, and the truth that specialised advertising and marketing and distribution groups have been nonetheless being constructed and optimized.
Gross revenue was roughly HK$487.6 million, representing a rise of 5.7% as in contrast with roughly HK$461.1 million in 2024, and gross revenue margin elevated by 0.2 share factors YoY to 83.2%. The Group delivered one other yr of record-breaking revenue, reaching roughly HK$93.3 million for the Yr, representing a rise of 12.7% YoY. Internet revenue margin elevated by 1.0 share factors YoY to fifteen.9%. These outcomes exhibit the Group’s success in changing product innovation into market worth by sturdy commercialization execution and monetary self-discipline. The earnings per share reached roughly HK$1.56 cents, reflecting a development of 15.5% YoY.
Prospects
Regenerative medication has emerged as a quickly growing discipline, targeted on repairing, changing, or regenerating broken tissues or organs utilizing cells, tissues, or genetic materials. The sector has the potential to deal with and handle the underlying causes of persistent and superior illnesses. The worldwide regenerative medication market was roughly USD51.7 billion in 2025. It’s projected to develop from USD63.0 billion in 2026 to USD555.6 billion by 2034, representing a compound annual development charge (CAGR) of 31.3%. The rising prevalence of persistent and hereditary illnesses, along with rising healthcare expenditure in each developed and rising markets, is predicted to help continued development within the regenerative medication business.
Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “In 2025, we’re proud to have delivered one other yr of report profitability, marking a major milestone in our development journey. In the course of the yr, we entered a brand new part of strategic growth. In anticipation of an more and more favorable market surroundings, we superior our strategic transition from ‘secure development’ to ‘innovation-driven’ growth, with a transparent concentrate on 4 diversified therapeutic areas: musculoskeletal regeneration, pores and skin regeneration, ocular regeneration, and ENT regeneration.
With a number of merchandise progressing by our pipeline and accelerating towards commercialization, the Group has continued to broaden its advertising and marketing channels. Along with strengthening our established offline hospital networks, deepening partnerships with native distributors, and internet hosting educational conferences, now we have actively expanded into on-line e-commerce platforms to reinforce product accessibility and lengthen our market attain. Our ambitions lengthen effectively past China. In the course of the yr, we shaped a strategic partnership with Kexing Biopharm to speed up the worldwide growth of Bogutai®. By means of this collaboration, now we have granted Kexing Biopharm unique commercialization rights for Bogutai® in six worldwide markets—Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico—laying a stable basis for world development. We anticipate these markets to start contributing income as early as the top of 2026. On the identical time, we’re advancing the FDA approval course of for Bogutai® in america, aiming for approval as early as 2027.
In December, we additionally entered right into a strategic collaboration with Wenzhou Medical College and the Folks’s Authorities of Ouhai District, Wenzhou, to foster a synergistic ‘authorities–college–enterprise’ mannequin, additional strengthening our capabilities in regenerative medication. Supported by sturdy partnerships with native governments and main educational establishments, we’re effectively positioned to construct a world-class biomedical ecosystem and improve our end-to-end innovation capabilities.”
Hashtag: #Uni-BioScience
The issuer is solely answerable for the content material of this announcement.
About Uni-Bio Science Group Restricted
Uni-Bio Science Group Restricted is an revolutionary biopharmaceutical enterprise listed on the Foremost Board of The Inventory Change of Hong Kong Restricted in 2001 (Inventory Code: 00690.HK). The Group is dedicated to powering the development of regenerative medication with next-generation artificial biology and complicated peptide innovation. Specializing in 4 core analysis areas—muscular-skeletal regeneration, pores and skin regeneration, ocular regeneration, and ENT regeneration—the Group has constructed a diversified product pipeline encompassing revolutionary biologics, high-value generic medicine, and medical aesthetics. The Group operates GMP-compliant manufacturing bases in Beijing, Dongguan, and Shenzhen, with absolutely built-in capabilities spanning R&D, manufacturing, and industrial gross sales. Uni-Bio Science Group is devoted to be the worldwide chief in regenerative medication, redefining how science restores and extends human life.
For additional info, please contact: 
ir@uni-bioscience.com
